Edition:
United States

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

19.15USD
14 Dec 2017
Change (% chg)

$-0.05 (-0.26%)
Prev Close
$19.20
Open
$19.09
Day's High
$19.88
Day's Low
$18.58
Volume
176,699
Avg. Vol
112,582
52-wk High
$31.23
52-wk Low
$8.10

Chart for

About

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense... (more)

Overall

Beta: --
Market Cap(Mil.): $1,274.27
Shares Outstanding(Mil.): 66.54
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.50 16.04
EPS (TTM): -- -- --
ROI: -- 15.11 35.70
ROE: -- 16.59 15.40

BRIEF-Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen

* Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS

Nov 15 2017

BRIEF-Akcea Therapeutics Q3 loss per share $0.27

* Q3 earnings per share view $-0.19, revenue view $11.9 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 06 2017

BRIEF-AKCEA PRESENTS DATA DEMONSTRATING SIGNIFICANT BURDEN OF ILLNESS IN FAMILIAL CHYLOMICRONEMIA SYNDROME

* AKCEA PRESENTS DATA DEMONSTRATING SIGNIFICANT BURDEN OF ILLNESS IN FAMILIAL CHYLOMICRONEMIA SYNDROME Source text for Eikon: Further company coverage:

Oct 16 2017

BRIEF-Akcea and Ionis announce filing of new drug submission for Volanesorsen to Health Canada

* Akcea and Ionis announce filing of new drug submission for volanesorsen to Health Canada

Sep 12 2017

BRIEF-Akcea Therapeutics establishes Canadian subsidiary

* Akcea Therapeutics Inc - Establishment of Ottawa-based Canadian unit and appointment of Jared Rhines as general manager for Akcea Therapeutics Canada Source text for Eikon: Further company coverage:

Sep 06 2017

BRIEF-Akcea Therapeutics says co announced Mike Maclean joins as CFO, effective August 31

* Akcea Therapeutics says on Sept 5, co announced Mike Maclean joined company as Chief Financial Officer, effective August 31- SEC filing Source text for Eikon: [http://bit.ly/2eIZHLj] Further company coverage:

Sep 05 2017

BRIEF-Akcea and Ionis submits New Drug Application for volanesorsen to FDA

* Akcea and Ionis announce submission of new drug application for volanesorsen to the U.S. FDA

Aug 31 2017

BRIEF-Akcea Q2 loss per share $0.41

* Akcea reports financial results and highlights for second quarter 2017

Aug 08 2017

BRIEF-Akcea, Ionis announce submission of marketing authorization application

* Akcea and Ionis announce submission of marketing authorization application for volanesorsen to the European Medicines Agency

Jul 27 2017

BRIEF-Novartis reports 9.7 pct passive stake in Akcea Therapeutics as of July 19

* Novartis Pharma AG reports 9.7 percent passive stake in Akcea Therapeutics Inc as of July 19, 2017 - ‍​SEC filing Source text for Eikon: Further company coverage:

Jul 27 2017

Earnings vs. Estimates